Development of Free Fatty Acid Receptor 4 (FFA4/GPR120) Agonists in Health Science

So-Eun Son, Nam-Jung Kim and Dong-Soon Im*

Department of Pharmacy, College of Pharmacy, and Department of Life and Nanopharmaceutical Sciences, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea

Abstract

Till the 21th century, fatty acids were considered as merely building blocks for triglycerides, phospholipids, or cholesteryl esters. However, the discovery of G protein-coupled receptors (GPCRs) for free fatty acids at the beginning of the 21th century opened up a new research field in pharmacology, merged into the field of receptor pharmacology for intercellular lipid mediators. Among the GPCRs for free fatty acids, free fatty acid receptor 4 (FFA4, also known as GPR120) recognizes long-chain polyunsaturated fatty acids such as DHA and EPA. It is significant in drug discovery because it regulates obesity-induced metaflammation and GLP-1 secretion. Our study reviews information on newly developed FFA4 agonists and their application in pathophysiologic studies and drug discovery. It also offers a potency comparison of the FFA4 agonists in an AP-TGF-α shedding assay.

Key Words: GPR120, FFA4, G protein-coupled receptor, Agonist, Drug development

INTRODUCTION

Fatty acids have been long considered as merely building blocks for triglycerides, phospholipids, or cholesteryl esters. However, the discovery of G protein-coupled receptors (GPCRs) for the free fatty acids at the beginning of the 21th century opened up a new research field in pharmacology, merged into the field of receptor pharmacology for intercellular lipid mediators (Im, 2013). Free fatty acid receptor 1 (FFA1, also known as GPR40), highly expressed in pancreatic β cells, regulates insulin secretion in response to medium and long-chain fatty acids in blood (Li et al., 2020). Free fatty acid receptors 2 and 3 (FFA2 and FFA3, also known as GPR43 and GPR41, respectively) recognize short-chain fatty acids produced by gut microbiota and regulate immune responses (Sun et al., 2017; Tan et al., 2017). Free fatty acid receptor 4 (FFA4, also known as GPR120) was initially cloned as an orphan GPCR (Fredriksen et al., 2003; Davenport et al., 2013). In 2005, FFA4 was found to regulate gut incretin glucagon-like peptide-1 (GLP-1) secretion in enteroendocrine L cells (Hirasawa et al., 2005). Considering that GLP-1 is an incretin hormone, the therapeutic potential of FFA4 agonists is drawing great attention in the treatment of diabetes by enhancing glucose-dependent secretion of insulin from pancreatic β cells. In 2010, FFA4 was found to suppress the inflammatory response in macrophages and regulate insulin-sensitizing and antidiabetic effects of omega-3 polyunsaturated fatty acids (Oh et al., 2010). Later, exon sequencing of FFA4 in obese European subjects revealed a deleterious non-synonymous mutation (p.R270H), inhibiting FFA4 signaling activity (Ichimura et al., 2012). FFA4 regulation of GLP-1 in the gut and obesity-induced metaflammation in the adipose tissue indicates promising applications of FFA4 agonists in metabolic disorders (Oh et al., 2010). In this article, we review the development of FFA4 agonists and compared their potencies in an AP-TGF-α shedding assay system (Inoue et al., 2012).

DEVELOPMENT OF SYNTHETIC FFA4 AGONISTS

GW9508

GW9508, (3-{4-[[3-(phenyloxy)phenyl](methyl)amino]phenyl}propanoic acid), was the first synthetic dual agonist of FFA1 and FFA4 (Fig. 1) (Briscoe et al., 2006). GW9508 stimulated intracellular Ca²⁺ mobilization in HEK293 cells expressing FFA1 and FFA4 (pEC₅₀ values of 7.32 and 5.46, respectively). Its potency towards FFA4 was 100-fold lower compared to FFA1 (Briscoe et al., 2006). GW9508 was used to study the role of FFA1 recep-
tors in processes such as the free fatty acid enhancement of glucose-stimulated insulin release and type 2 diabetes (Graciano et al., 2013). In glucose tolerance studies, the administration of GW9508 significantly reduced plasma glucose and augmented insulin release in mice (Moran et al., 2014).

**GW9508 application in only FFA4-expressing cells:** Despite the dual agonism of GW9508, it was used to specifically study FFA4 functions on several occasions. One occasion was when FFA1 expression was not detected or was negligible such as in ghrelin-producing cells, rat hypothalamic cells, murine bone marrow cultures, and human eosinophils (Cornish et al., 2008; Gong et al., 2014; Wellhauser and Belsham, 2014; Konno et al., 2015). Ghrelin is produced in the gut, and is often called the hunger hormone, because ghrelin signals the brain to become hungry and seek out food (Nakazato et al., 2001). Endogenous ghrelin levels are increased by fasting and decreased immediately after feeding. The activation of FFA4 by long-chain polyunsaturated fatty acids was studied as a mechanism of plasma ghrelin decrement after feeding (Gong et al., 2014). In ghrelin-producing SG-1 cells, mRNA of FFA4 is expressed, but not FFA1 (Gong et al., 2014). Treatment with GW9508 or α-linolenic acid (α-LA) significantly inhibited ghrelin secretion in vitro, and this inhibition was absent in FFA4 knockdown cells (Gong et al., 2014). In addition, administration of GW9508 prevented fasting-induced plasma ghrelin elevation in vivo. Therefore, the decrease in plasma ghrelin levels after feeding is partially controlled by FFA4 activation in response to long-chain polyunsaturated fatty acids in the food (Gong et al., 2014).

In rHypoE-7 cells, an immortalized hypothalamic neuronal cell line, FFA4 expression was high but FFA1 was not detectable (Wellhauser and Belsham, 2014). Therefore, GW9508 was used to validate DHA FFA4 activation to prevent neuronal inflammation (Wellhauser and Belsham, 2014). GW9508 was used as a dual FFA1/FFA4 agonist on osteoclastogenesis in murine bone marrow cultures, and it mimicked the anti-osteoclastogenesis actions of stearic acids (Cornish et al., 2008). Because FFA4 expression was 100-fold higher than FFA1 expression, FFA4 was proposed as the receptor for the anti-osteoclastogenic effects of fatty acids (Cornish et al., 2008). This was later confirmed using FFA4 knockdown cells and KO mice (Ahn et al., 2016; Kim et al., 2016). Due to the negligible expression of FFA1 in eosinophils, GW9508 was used to study FFA4 functions in human eosinophils, where FFA4 activation significantly induced IL-4 secretion from eosinophils (Konno et al., 2015). GW9508 was also used to study the role of FFA4 signaling in promoting angiogenic switching and motility of human colorectal carcinoma cells, because there was no detectable expression of FFA1 (Wu et al., 2013). FFA4 expression is induced in colorectal carcinoma tissues and cell lines in association with tumor progression (Wu et al., 2013).

**GW9508 application in combination with siRNA technique:** GW9508 was also used to demonstrate the role of FFA4 in the regulation of inflammatory response in cyclophosphamide-
induced interstitial cystitis. Interstitial cystitis is a clinical syndrome characterized by urinary frequency, nocturia, and pelvic pain with unknown etiology (Pataika et al., 2017). GW9508 treatment inhibited cyclophosphamide-induced inflammatory responses in RT4 urothelial cells through suppression of NF-κB translocation from the cytosol to the nucleus (Chen et al., 2018a). This anti-inflammatory effect was abolished by FFA4 antagonist AH7614 or siRNA transfection of FFA4 (Chen et al., 2018a). Furthermore, the significantly increased inflammatory cell infiltration as well as the impaired urothelial integrity of the bladder after cyclophosphamide treatment were reversed in vivo by GW9508 treatment in combination with extracorporeal shock wave (Chen et al., 2018a). Treatment with GW9508 in vivo protected the liver against ischemia-reperfusion injury, and pretreatment with FFA4-siRNA suggested FFA4 in Kupffer cells as a mediator of the effects in the liver (Raptis et al., 2014).

**GW9508 application in combination with GW1100 (FFA1 antagonist):** Although FFA1 expression was detected, GW9508 was utilized in combination with GW1100, an FFA1 antagonist in colon cancer cells, osteosarcoma, pituitary cultures, and enterodocrine L cells (Garrel et al., 2011; Wu et al., 2013; Takahashi et al., 2017, 2018). In colon cancer DLD1 cells, treatment with GW9508 in combination with FFA4 knockdown cells and GW1100 treatment revealed that both FFA1 and FFA4 are involved in the regulation of cellular function during tumor progression by inhibiting cell motility (Takahashi et al., 2018).

Therefore, GW9508 has been utilized to find out the functions of FFA4 in multiple cells and organs, although it is a dual agonist of FFA1 and FFA4. In several cell lines, FFA1 expression was not detectable or was negligible, and in other cases, FFA4 knockdown cells or KO mice were used to support the function of FFA4. Sometimes, the FFA1 antagonist GW2011 was useful to exclude the possibility of FFA1 involvement.

**NGC21**

NGC21, [4-{4-[2-(Phenyl-pyridin-2-yl-amino)-ethoxy]-phenyl}butyric acid], was developed as a selective agonist of FFA4 by screening derivatives of peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists (Fig. 1) (Suzuki et al., 2008). It has a 10-fold higher selectivity to FFA4 over FFA1 (Suzuki et al., 2008). NGC21 activates extracellular signal-regulated kinase (ERK) in FFA4 expressing HEK293 cells, and increases intracellular Ca2+ concentrations and GLP-1 secretion in murine enterodocrine STC-1 cells, which endogenously express FFA4 (Suzuki et al., 2008). Administration of NGC21 into the mouse colon resulted in an increase in plasma GLP-1 levels, implying in vivo efficacy on enterodocrine L cells (Sun et al., 2010).

**Grifolic acid**

Grifolic acid, [2,4-Dihydroxy-6-methyl-3-{[2(E,6E)-3,7,11-trimethyl-2,6,10-dodecatrien-1-yl]-benzoic acid}], was found to be a partial agonist of FFA4 by screening lipids of acidic structure (Fig. 1) (Hara et al., 2009). It activated ERK and increased intracellular Ca2+ concentrations in FFA4-expressing cells, but not in FFA1 cells (Hara et al., 2009). However, its activation of FFA4 was not the same as that of nLA, and it inhibited the αLA-induced activation of ERK and Ca2+ response in FFA4 expressing cells (Hara et al., 2009). Grifolic acid was used to test whether FFA4 activation affects ghrelin secretion in vitro in MGN3-1 ghrelinoma cells, but no effect was observed (Janssen et al., 2012). However, administration of grifolic acid increased plasma ghrelin levels in vivo (Janssen et al., 2012).

**TUG-891**

TUG-891, 3-{4-[(4-fluoro-4'-methyl-[1,1'-biphenyl]-2-yl)methoxy]phenyl}propanoic acid, has been reported as a potent selective agonist for FFA4 (Fig. 1) (Shimpukade et al., 2012). In various assay systems, such as Ca2+ mobilization, β-arrestin recruitment, and ERK phosphorylation, TUG-891 showed properties similar to nLA in human FFA4-expressing cells (Hudson et al., 2013). FFA4 activation by TUG-891 induces rapid phosphorylation of FFA4 and subsequent internalization (Hudson et al., 2013). TUG-891 showed potent agonism on both mouse and human FFA4. However, its selectivity for mouse FFA4 over mouse FFA1 was not high, resulting in limitation of its use in rodent species in vivo (Hudson et al., 2013; Suckow and Briscoe, 2017). Although TUG-891 is an orally available, potent, and selective agonist for human FFA4, its use in experimental therapeutics should be carefully interpreted, because its action could result from FFA1 in rodents (Hudson et al., 2013; Suckow and Briscoe, 2017).

Nevertheless, oral administration of TUG-891 through water intake not only ameliorated inflammation in visceral white adipose tissue and insulin resistance, but also suppressed increased food intake and weight gain induced by sleep fragmentation in mice (Go zal et al., 2016). FFA4 is highly expressed in brown adipose tissue and its expression increases further under cold conditions (Christian, 2020). TUG-891 administration induced stimulation of mitochondrial breathing in brown adipose tissue, resulting in enhancement of fat oxidation and reduction of fat mass in mice (Schilperoort et al., 2018). TUG-891 stimulation of brown adipocytes induces an intracellular Ca2+ increase, resulting in elevated consumption of O2 and mitochondrial fission and depolarization (Christian, 2020). Therefore, FFA4 activation by TUG-891 increased fat oxidation and reduced fat mass in mice (Christian, 2020).

TUG-891 was used to elucidate FFA4 function in the tongue in relation to taste preference for fats. In cultured mouse and human taste bud cells, TUG-891 treatment induced a rapid increase in intracellular Ca2+, induced ERK1/2 phosphorylation, and enhanced release of GLP-1 (Murtaza et al., 2020). Direct lingual application of TUG-891 altered circulating concentrations of cholecystokinin and adipokines, associated with decreased circulating LDL in conscious mice (Murtaza et al., 2020). Binding of TUG-891 to lingual FFA4 seems to activate the tongue-brain-gut axis and modulate taste preference for fats (Murtaza et al., 2020). TUG-891 was also used in a cisplatin-induced acute kidney injury model. Treatment with TUG-891 ameliorated cisplatin-induced acute kidney injury by repressing ER stress and apoptosis in tubular epithelial cells through FFA4 activation (Huang et al., 2020). In mouse alveolar macrophages, TUG-891 was used to investigate FFA4 function in phagocytosis. Treatment with TUG-891 inhibited the motility and phagocytosis of alveolar macrophages via a Gq protein-PLC-Ca2+ release pathway (Su et al., 2020). FFA4-mediated phagocytosis was counteracted by LPS treatment (Zhao et al., 2019). LPS treatment inhibited FFA4 expression in the mouse macrophage cell line, Ana-1, and in mouse alveolar macrophages both in vitro and in vivo (Zhao et al., 2019).

Based on the two findings that FFA4 activation induces M2 polarization in macrophages and M2 phenotype macrophages protect the kidney against renal interstitial fibrosis, an interesting in vivo experiment was conducted. Peritoneal...
macrophages from rats were incubated with TUG-891 in vitro for 24 h, and then transplanted autologously into the kidney with ureteral obstruction by intrarenal injection for 7 days on the same day following unilateral ureteral obstruction operation (Wang et al., 2019). TUG891-programmed macrophages upregulated the expression of M2 markers CD206 and arginase-1, while the expression of M1 markers IL-6 and TNF-α was downregulated (Wang et al., 2019). Increased renal interstitial fibrosis following the operation was markedly alleviated by TUG891-programmed macrophages, but not by untreated macrophages (Wang et al., 2019). To interpret the relevant function of FFA4 in the differentiation of 3T3-L1 adipocytes, TUG-891 was used because natural ligands DHA and ωLA showed different effects in the cells (Song et al., 2016). FFA4 expression was increased along with the adipogenic differentiation of 3T3-L1 adipocytes, and the adipogenic ability of TUG-891 was significantly inhibited in FFA4 knockout cells (Song et al., 2016). Although TUG-891 has a highly selective activity on human FFA4 over FFA1, its selectivity for mouse FFA4 over mouse FFA1 was not convincing. However, in combination with siRNA technology and KO mice, TUG-891 has been used as a tool for FFA4.

GSK137647A

GSK137647A, [4-methoxy-N-(2,4,6-trimethylphenyl)benzenesulfonamide], was developed by GlaxoSmithKline as the first non-carboxylic FFA4 agonist (pEC<sub>50</sub>=6.3) (Fig. 1) (Sparks et al., 2014). Based on this report, it has 50-fold higher selectivity for FFA4 over FFA1 and preserved activity across species (Sparks et al., 2014).

GSK137647A was used to investigate FFA4 function on the osteogenic and adipogenic differentiation of bone mesenchymal stem cells of db/db mice (Wang et al., 2020). GSK-137647A showed a significant increase in mineralization of differentiated osteoblasts compared to the control group and elevated alkaline phosphatase activity in a time-dependent manner, while it suppressed the adipogenic differentiation of bone mesenchymal stem cells (Wang et al., 2020).

In vitro and ex vivo treatments of pancreatic β MIN6 cells and islets isolated from wild-type mice, GSK137647A restored pancreatic duodenal homeobox-1 expression levels and β-cell function by inhibiting palmitic acid-induced elevation of proinflammatory chemokines and activation of NF-κB, JNK1/2, and p38MAPK signaling pathways (Wang et al., 2019). The protective effects were not observed in FFA4 knockout MIN6 cells and islets isolated from FFA4 KO mice (Wang et al., 2019). GSK137647A supplementation ameliorated glucose tolerance and insulin sensitivity as well as improved pancreatic duodenal homeobox-1 expression and islet inflammation in mice with diet-induced obesity, but not in FFA4 KO mice (Wang et al., 2019).

GSK137647 attenuated both basal and LPS-induced production of IL-6 and CCL2 in 3T3-L1 adipocytes (Hasan et al., 2017). The expression of MMP-9, MMP-3, and tissue inhibitor of metalloproteinase-1 were attenuated in RAW 264.7 macrophages grown in conditioned medium collected from GSK137647-treated adipocytes (Hasan et al., 2017). FFA4 activation in adipocytes could reduce macrophage migration via a paracrine mechanism (Hasan et al., 2017).

**Compound A**

Compound A was developed by Merck as an orally available, selective FFA4 agonist (EC<sub>50</sub>=0.35 µM) (Fig. 1) (Oh et al., 2014). Its activation on FFA1 is negligible (Oh et al., 2014). Compound A showed anti-inflammatory effects in macrophages in vitro (Oh et al., 2014). Administration of compound improved glucose tolerance, decreased hyperinsulinemia, increased insulin sensitivity, and decreased hepatic steatosis in obese mice fed a high-fat diet (Oh et al., 2014). Recently, compound A was used to verify that beneficial effects of DHA on atopic dermatitis is mediated through FFA4 activation and Foxp3<sup>+</sup> Treg increase in combination with FFA4 KO mice (Son et al., 2020).

**Metabolex compounds**

Metabolex 36 and metabolex compound B, developed by the company Metabolex (now Cymabay Therapeutics) have been used as FFA4 agonists in several studies (Fig. 1). Metabolex 36 was used to study FFA4 function in pancreatic β cells along with AstraZeneca compounds (AZ-423 and AZ-670) (Stone et al., 2014). Glucose-induced somatostatin secretion from murine islets was inhibited by FFA4 agonists, but not in FFA4 KO mice (Stone et al., 2014). Metabolex 36 has a pEC<sub>50</sub> value of 5.9 on FFA4 and less than 4.0 on FFA1 (Stone et al., 2014). Compound B was used to investigate the role of FFA4 in ghrelin secretion and somatostatin release in combination with FFA4 KO mice (Engelstoft et al., 2013; Egerod et al., 2015). Compound B had EC<sub>50</sub>=15 nM on FFA4 and 1000-fold selectivity over FFA1 in inositol trisphosphate accumulation assays in FFA4-transfected COS7 cells (Engelstoft et al., 2013). Compound B inhibited basal ghrelin secretion from primary gastric mucosal cells but not in cells isolated from FFA4 KO mice (Engelstoft et al., 2013). Oral administration of compound B decreased plasma ghrelin under fasting conditions in mice (Engelstoft et al., 2013). Compound B also inhibited somatostatin release from primary gastric epithelial cells, but was not in cells isolated from FFA4 KO mice (Egerod et al., 2015).

**TUG-1197**

TUG-1197 (compound 34 in the paper) was developed from a series of cyclic sulfonamide FFA4 agonists disclosed by Banyu Pharmaceutical (Fig. 1) (Azevedo et al., 2016; Hansen and Ulven, 2017). TUG-1197 has pEC<sub>50</sub>=6.6 and 6.8 in Ca<sup>2+</sup> mobilization assay on human FFA4 and murine FFA4, respectively (Azevedo et al., 2016; Hansen and Ulven, 2017). In mice with diet-induced obesity, TUG-1197 treatment improved glucose tolerance and increased insulin sensitivity in an FFA4-dependent manner (Azevedo et al., 2016).

**KDT501**

KDT501 is an orally administered isohumulone structure derived from hop extracts and designed to help control impaired glucose and insulin regulation in patients with insulin resistance. The agonist activity of KDT501 on FFA4 was estimated as EC<sub>50</sub>=30.3 µM and a partial agonism on PPARγ [US patents 2012/0108671A1]. Nonclinical studies have shown that administration of KDT501 improved insulin sensitivity and glucose regulation as well as reduced proinflammatory signals (Konda et al., 2014).
NATURAL AGONISTS OF FFA4

Natural long-chain fatty acids are recognized as endogenous ligands of FFA4 (Davenport et al., 2013). Initially, saturated fatty acids with a chain length of C14 to C18 and unsaturated fatty acids with chain length of C16 to C22 were found to activate FFA4 (Hirasawa et al., 2005), which was later confirmed (Christiansen et al., 2015). Omega-3 polyunsaturated fatty acids, including αLA, DHA, EPA, and pinolenic acid, showed higher potency than other fatty acids, and natural polyunsaturated fatty acids are all dual agonists for FFA4 and FFA1 (Christiansen et al., 2015; Ulven and Christiansen, 2015). Natural fatty acids such as DHA and EPA have also been utilized to determine the functions of FFA4 in various cells and animal models. However, caution should be exercised while using DHA and EPA as tools for FFA4 activation because they could exert actions via other molecular targets such as FFA1, PPARα, RXRα, or their conversion to pro-resolving mediators such as resolvin E series, protectin D1, and maresin 1 (Im, 2012; Ulven and Christiansen, 2015; Serhan et al., 2018). Nevertheless, DHA, EPA, and αLA have been used as natural ligands for FFA4.

EPA treatment alleviated cerebral ischemia injury by preventing acute cerebral infarction-induced inflammation via the inhibition of NLRP3 inflammasome activation, which was not observed in FFA1 and FFA4 double knockout mice (Mo et al., 2020). Treatment with EPA or DHA significantly increased the protein level of FFA4 in RAW264.7 cells and increased the proliferation index in RAW264.7 cells (Han et al., 2017). Using DHA supplementation and FFA4 KO mice, FFA4 was identified as an inhibitor of dendritic cell maturation (Zhao et al., 2020). DHA induced a tolerogenic dendritic cell phenotype and enhanced regulatory T cell population in vivo through FFA4 (Zhao et al., 2020).

Administration of DHA showed promising results in experimental chronic colitis and body weight loss improvement. IL-10 KO mice display the most similar characteristics to those of human Crohn’s disease (Zhao et al., 2017). In the DHA-treated mice, enhanced expression and improved distribution integrity of protein FFA4 were observed, which was probably associated with the regulation of the TAK1/IKK-α/IKBa/p65 pathway, which might be an important target for Crohn’s colitis (Zhao et al., 2017). FFA4 levels were downregulated in osteoarthritis patients compared with control subjects, whereas FFA4 activation with DHA exhibited anti-inflammatory effects in primary human chondrocytes in vitro (Chen et al., 2018b). FFA4 agonism with DHA enhanced wound repair and healing of a skin defect model in mice, as shown by the downregulation of CD68+ cell numbers (Chen et al., 2018b).

In 2014, lipidomic analysis of mice overexpressing the Glut4 glucose transporter in adipocytes revealed structures of branched fatty acid esters of hydroxy fatty acids (e.g., palmitic-acid-9-hydroxy-stearic-acid, 9-PAHSA) as endogenous ligands for FFA4 (Yore et al., 2014). In adipocytes, 9-PAHSA enhanced insulin-stimulated glucose uptake through FFA4 (Yore et al., 2014).

FFA4 ANTAGONIST

AH-7614

AH-7614 (compound 39 in the paper) was first described as an antagonist of FFA4, that is, AH-7614 inhibited FFA4 activation by GSK137647A and linoleic acid (Fig. 1) (Sparks et al., 2014). AH-7614 is a negative allosteric modulator of FFA4 (Sparks et al., 2014). GSK137647A inhibited differentiation towards adipocyte phenotype in a mouse mesenchymal stem cell line and consistently inhibited endogenous signaling of FFA4 (Watterson et al., 2017). Effects of arachidonic acid on FFA4 are also inhibited by AH-7614 (Villegas-Comonfort et al., 2017).

![Concentration-response curves of FFA4 agonists in an AP-TGF-α shedding assay.](https://doi.org/10.4062/biomolther.2020.213)
AH-7614 was used to prove FFA4 involvement in cyclophosphamide-induced bladder interstitial cystitis by inhibiting the inflammatory response in bladder cells (Chen et al., 2018a). Protective effect of DHA on non-alcoholic fatty liver disease was studied in an in vitro model of liver X receptor-mediated hepatocellular steatosis. DHA-induced inhibition of lipid accumulation was blunted by treatment of AH-7614 and not observed in primary hepatocytes from FFA4 deficient mice (Kang et al., 2018).

Comparing FFA4 agonist activities

Commercially available agonists for FFA4 are limited. We compared the available potency of FFA4 agonists in an AP-TGF-α shedding assay system (Inoue et al., 2012). As shown in Fig. 2, compound A and TUG-891 showed the highest potency, followed by GW9508. GSK137647A was not as potent as compound A and TUG-891, and its efficacy was not as high as that of GW9508 (Fig. 2). Natural fatty acids DHA and EPA showed some activity, but their potency was lower than that of synthetic agonists.

Table 1. Synthetic FFA4 agonists and their applications in FFA4-mediated pathophysiologic functions

| Synthetic agonist       | FFA4-mediated functions                                                                 | Reference                                                                 |
|-------------------------|-----------------------------------------------------------------------------------------|---------------------------------------------------------------------------|
| GW9508                  | Enhancement of glucose-stimulated insulin release                                       | Graciano et al., 2013                                                    |
|                         | Reduction of plasma glucose                                                            | Moran et al., 2014                                                       |
|                         | Inhibition of inflammatory responses                                                   | Raptis et al., 2014                                                       |
|                         | Decrease of ghreline secretion                                                         | Gong et al., 2014                                                        |
|                         | Prevention of neuronal inflammation                                                    | Wellhauser and Belsham, 2014                                              |
|                         | Anti-osteogenesis                                                                      | Ahn et al., 2016; Kim et al., 2016                                       |
|                         | Induction of IL-4 secretion from eosinophils                                           | Konno et al., 2015                                                       |
|                         | Promotion of angiogenesis and motility in colorectal carcinoma                        | Wu et al., 2013                                                          |
| NCG21, grifolic acid    | Increase of GLP-1 secretion                                                            | Suzuki et al., 2008; Sun et al., 2010; Janssen et al., 2012              |
| TUG-891                 | Amelioration of metaflammation and insulin resistance                                  | Gozal et al., 2016                                                       |
|                         | Increase of fat oxidation and reduction of fat mass                                    | Schilperoort et al., 2018; Christian, 2020                               |
|                         | Increase of GLP-1 secretion                                                            | Murtaza et al., 2020                                                     |
|                         | Decrease of circulating LDL                                                             | Murtaza et al., 2020                                                     |
|                         | Amelioration of acute kidney injury                                                    | Huang et al., 2020                                                       |
|                         | Inhibition of motility and phagocytosis in alveolar macrophages                        | Zhao et al., 2019                                                        |
|                         | Induction of M2 polarization                                                          | Wang et al., 2019                                                        |
|                         | Induction of adipogenic differentiation                                               | Song et al., 2016                                                        |
| GSK137647A              | Increase in mineralization of differentiated osteoblasts                              | Wang et al., 2020                                                        |
|                         | Suppression of adipogenic differentiation of mesenchymal stem cells                   | Wang et al., 2020                                                        |
|                         | Protection of pancreatic β cell dysfunction                                           | Wang et al., 2019                                                        |
|                         | Inhibition of islet inflammation                                                       | Wang et al., 2019                                                        |
|                         | Attenuation of IL-6 and CCL2 production in adipocytes                                  | Hasan et al., 2017                                                       |
| Compound A              | Anti-inflammation in macrophages                                                       | Oh et al., 2014                                                          |
|                         | Improvement of glucose tolerance                                                     | Oh et al., 2014                                                          |
|                         | Decrease of hyperinsulinemia                                                          | Oh et al., 2014                                                          |
|                         | Increase of insulin sensitivity                                                       | Oh et al., 2014                                                          |
|                         | Decrease of hepatic steatosis                                                          | Oh et al., 2014                                                          |
|                         | Amelioration of atopic dermatitis                                                     | Son et al., 2020                                                         |
| Metabolex 36, Compound B| Suppression of somatostatin secretion from pancreatic δ cells                        | Stone et al., 2014                                                       |
|                         | Inhibition of ghrelin secretion                                                      | Engelstoft et al., 2013; Egerod et al., 2015                             |
|                         | Inhibition of somatostatin secretion from gastric epithelial cells                     | Egerod et al., 2015                                                      |
| TUG-1197                | Improvement of glucose tolerance                                                     | Azevedo et al., 2016                                                     |
|                         | Increase of insulin sensitivity                                                        | Azevedo et al., 2016                                                     |
| KDT501                  | Improvement of insulin sensitivity                                                     | Konda et al., 2014                                                       |
|                         | Improvement of glucose regulation                                                     | Konda et al., 2014                                                       |
|                         | Reduction of proinflammatory signals                                                  | Konda et al., 2014                                                       |
|                         | Reduction of plasma triglycerides                                                     | Kern et al., 2017                                                       |
|                         | Increase of plasma adiponectin                                                        | Kern et al., 2017                                                       |
of other synthetic FFA4 agonists (Fig. 2). 9-PAHSA did not show any activity in the AP-TGF-α shedding assay system (not shown in the Figure).

**CLINICAL TRIALS TARGETING FFA4**

There are completed and ongoing clinical trials with natural and synthetic FFA4 agonists. The ongoing human trial is titled “Effects of pine nut and olive oil as FFA1/FFA4 and GPR119 agonists on glucose tolerance in healthy overweight or obese subjects” NCT03774095 (https://www.clinicaltrials.gov). Pine nut oil contains about 20% pinolenic acid, which has been shown to be an equipotent natural dual agonist of FFA1 and FFA4, and also improves glucose tolerance in mice (Christiansen et al., 2015). Olive oil contains mono-unsaturated oleic acid (61-80%), which can be transformed during digestion to 2-oleoylglycerol, an agonist of GPR119 (Hansen et al., 2011). Activation of three receptors (FFA1/FFA4 and GPR119) with pinolenic acid and 2-oleoylglycerol from pine nut oil and olive oil, respectively, may enhance or synergize GLP-1 secretion from enterodocrine cells and enhance glucose-stimulated insulin secretion from pancreatic β cells. Outcomes of the clinical trial would be useful for building therapeutic strategies for diabetes and obese patients.

The other completed clinical trial related to FFA4 was “Effects of KDT501 on metabolic features in insulin-resistant subjects”, that is, NCT02444910 (https://www.clinicaltrials.gov). KDT501 was well tolerated in nine insulin-resistant pre-diabetic humans, and treatment with KDT501 reduced plasma triglycerides and TNF-α, while plasma adiponectin increased significantly (Kern et al., 2017). The systemic effects might come from KDT501 ability to potentiate β-adrenergic signaling and enhance mitochondrial function in adipocytes of subcutaneous white adipose tissue (Finlin et al., 2017).

**CLOSING REMARKS**

Since the identification of FFA4 as a receptor for polyunsaturated fatty acids in 2005, many efforts have been made to synthesize selective and potent agonists of FFA4. Among natural agonists, DHA and EPA are the most potent, while compound A and TUG-891 are the most potent synthetic agonists. Despite having dual agonism for FFA1 and FFA4, GW9508 has been primarily used as a tool for FFA4 research. The limitation of FFA1/4 dualism has been overcome by combining GW9508 with GW1100 (FFA1 antagonist) or combination with FFA4 knockdown cells or mice. In certain cell types, FFA1 expression was null or not detectable, resulting in observation of only FFA4-activated functions with GW9508. There- fore, GW9508 has been efficiently applied to elucidate FFA4 functions. However, for the therapeutic applications, FFA4 agonists with better pharmacokinetic and pharmacodynamic properties should be developed, especially for human trials.

In summary, there are accumulating data to support the beneficial functions of FFA4 in metabolic and inflammatory diseases (Table 1). Pharmacological tools for FFA4 research are available to apply, but not many. Clinical trials with natural agonists for FFA1/FFA4/GPR119 or synthetic derivatives for FFA4 and PPARα are progressing for obesity and diabetes. We would like to close this article with the hope to find more pathophysiological significance of FFA4 in human bodies and to see FFA4 agonists (natural or synthetic) in use for the treatment of human diseases in the future.

**ACKNOWLEDGMENTS**

This research was supported by the Basic Research Laboratory Program (BRL) and the Basic Science Research Program of the Korean National Research Foundation funded by the Korean Ministry of Science, ICT and Future Planning (NRF-2020R1A4A1016142 and NRF-2019R1A2C1005523).

**REFERENCES**

Ahn, S. H., Park, S. Y., Baek, J. E., Lee, S. Y., Baek, W. Y., Lee, S. Y., Lee, Y. S., Yoo, H. J., Kim, H., Lee, S. H., Im, D. S., Lee, S. K., Kim, B. J. and Koh, J. M. (2016) Free fatty acid receptor 4 (GPR120) stimulates bone formation and suppresses bone resorption in the presence of elevated n-3 fatty acid levels. *Endocrinology* **157**, 2621-2635.

Azevedo, C. M., Watsoner, K. R., Wargent, E. T., Hansen, S. V., Hudson, B. D., Kepczynska, M. A., Dunlop, J., Shimpukade, B., Christiansen, E., Milligan, G., Stocker, C. J. and Uven, T. (2016) Non-acidic free fatty acid receptor 4 agonists with anti-diabetic activity. *J. Med. Chem.* **59**, 8868-8878.

Briscoe, C. P., Peat, A. J., McKeown, S. C., Corbett, D. F., Goetz, A. S., Littleton, T. R., McCoy, D. C., Kenakin, T. P., Andrews, J. L., Ammaia, C., Formwald, J. A., Ignar, D. M. and Jenkinson, S. (2006) Pharmacological regulation of insulin secretion in Min6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules. *Br. J. Pharmacol.* **148**, 619-628.

Chen, Y. L., Lin, Y. P., Sun, C. K., Huang, T. H., Yip, H. K. and Chen, Y. T. (2018a) Extracorporeal shockwave against inflammation mediated by GPR120 receptor in cyclophosphamide-induced rat cystitis model. *Mol. Med.* **24**, 60.

Chen, Y., Zhang, D., Ho, K. W., Lin, S., Suen, W. C., Zhang, H., Zha, Z. L. and Leung, P. S. (2018b) GPR120 is an important inflammatory regulator in the development of osteoarthritis. *Arthritis Res. Ther.* **20**, 163.

Christian, M. (2020) Elucidation of the roles of brown and brite fat genes: GPR120 is a modulator of brown adipose tissue function. *Exp. Physiol.* **105**, 1201-1205.

Christiansen, E., Wattersen, K. R., Stocker, C. J., Sokol, E., Jenkins, L., Simon, K., Grundmann, M., Petersen, R. K., Wargent, E. T., Hudson, B. D., Kostenis, E., Ejsing, C. S., Crawthorne, M. A., Milligan, G. and Uven, T. (2015) Activity of dietary fatty acids on FFA1 and FFA4 and characterisation of pinolenic acid as a dual FFA1/ FFA4 agonist with potential effect against metabolic diseases. *Br. J. Nutr.* **113**, 1677-1688.

Cornish, J., MacGibbon, A., Lin, J. M., Watson, M., Callon, K. E., Tong, P. C., Dunford, J. E., van der Does, Y., Williams, G. A., Grey, A. B., Naot, D. and Reid, I. R. (2008) Modulation of osteoclastogenesis by fatty acids. *Endocrinology* **149**, 5688-5695.

Davenport, C. P., Alexander, S. P., Sharman, J. L., Pawson, A. J., Benson, H. E., Monaghan, A. E., Liew, W. C., Mpamhanga, C. P., Bonner, T. T. and Neubig, R. R. (2013) International union of basic and clinical pharmacology. LXXVIII. G protein-coupled receptor antagonist: recommendations for new pairings with cognate ligands. *Pharma- col. Rev.* **65**, 967-986.

Egerod, K. L., Engelstoft, M. S., Lund, M. L., Grunddal, K. V., Zhao, M., Barir-Jensen, D., Nygaard, E. B., Petersen, N., Holst, J. J. and Schwartz, T. W. (2015) Transcriptional and functional characterization of the g protein-coupled receptor repertoire of gastric somatostatin cell. *Endocrinology* **156**, 3909-3923.

Engelstoft, M. S., Park, W. M., Sakata, I., Kristensen, L. V., Husted, A. S., Osborne-Lawrence, S., Piper, P. K., Walker, A. K., Pedersen, M. H., Nohr, M. K., Pan, J., Sinz, C. J., Carrington, P. E., Akiyama,
Son et al. Development of FFA4 Agonists

T. E., Jones, R. M., Tang, C., Ahmed, K., Offermanns, S., Egerod, K. L., Zigman, J. M. and Schwartz, T. W. (2013) Seven transmembrane G-protein coupled receptor repertoire of gastric ghrelin cells. Mol. Metab. 2, 376-392.

Finlin, B. S., Zhu, B., Kok, B. P., Godio, C., Westgate, P. M., Grayson, N., Sims, R., Bland, J. S., Saez, E. and Kern, F. A. (2017) The influence of a KĐT501, a novel isohumulone, on adipocyte function in humans. Front. Endocrinol. 8, 255.

Fredriksson, R., Lagerström, M. C., Lundin, L. and Schöltz, H. B. (2003) The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol. Pharmacol. 63, 1256-1272.

Garrel, G., Simon, V., Denoyelle, C., Cruciani-Guglielmi, C., Mingranne, S., Cournis, R., Magnan, C. and Cohen-Tannoudji, J. (2011) Unsaturated fatty acids stimulate LH secretion through novel PKC epsilon and -theta in gonadotrope cells and inhibit GnRH-induced LH release. Endocrinology 152, 3905-3916.

Gong, Z., Yoshimura, M., Aizawa, S., Kurotani, R., Zigman, J. M., Sakai, T. and Sakata, I. (2014) G protein-coupled receptor 120 signaling regulates ghrelin secretion in vivo and in vitro. Am. J. Physiol. Endocrinol. Metab. 306, E28-E35.

Gozal, D., Qiao, Z., Almendros, I., Zheng, J., Khalyfa, A., Shimpukade, B. and Ulven, T. (2016) Treatment with TUG891, a free fatty acid receptor 4 agonist, restores adipose tissue metabolic dysfunction following chronic sleep fragmentation in mice. Int. J. Obes. (Lond.) 40, 1143-1149.

Graciano, M. F., Valle, M. M., Curi, R. and Carpinelli, A. R. (2013) Evidence for the involvement of GPR40 and NADPH oxidase in palmitic acid-induced superoxide production and insulin secretion. Islets 5, 139-148.

Han, L., Song, S., Niu, Y., Meng, M. and Wang, C. (2017) Eicosapentaenoic acid (EPA) induced macrophages activation through GPR120-mediated Ral-ERK1/2-IKK-NF-κB p65 signaling pathways. Nutrients 9, 937.

Hansen, K. B., Rosenkilde, M. M., Knop, F. K., Wellner, N., Diep, T. A., Rehfeld, J. F., Andersen, U. B., Holst, J. J. and Hansen, H. S. (2011) 2-Oleoyl glycerol is a GPR119 agonist and signals GLP-1 release in humans. J. Clin. Endocrinol. Metab. 96, E1409-E1417.

Hara, S. V. and Ulven, T. (2017) Pharmacological tool box for the free fatty acid receptor 4 (FFA4/GPR120). Handb. Exp. Pharmacol. 236, 33-56.

Hara, T., Hirasaki, A., Sun, Q., Sadakane, K., Iitsu, C., Iga, T., Adachi, T., Koshimizu, T. A., Hashimoto, T., Asakawa, Y. and Tsujimoto, G. (2009) Novel selective ligands for free fatty acid receptors GPR120 and GPR40. Naunyn Schmiedebergs Arch. Pharmacol. 380, 247-255.

Hasan, A. U., Ohmori, K., Hashimoto, T., Kamitori, K., Yamaguchi, F., Noma, T., Igarashi, J., Tsuibo, K., Tokuda, M., Nishiyama, A. and Kohno, M. (2017) GPR120 in adipocytes has differential roles in the production of pro-inflammatory adipokynes. Biochem. Biophys. Res. Commun. 486, 78-82.

Hirasaki, A., Tsumaya, K., Awaai, T., Katsuma, S., Adachi, T., Yamauchi, A., Sugimoto, Y., Miyazaki, S. and Tsujimoto, G. (2005) Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat. Med. 11, 90-94.

Huang, Z., Guo, F., Xia, Z., Liang, Y., Lei, S., Tan, Z., Ma, L. and Fu, P. (2020) Activation of GPR120 by TUG591 ameliorated cisplatin-induced acute kidney injury via repressing ER stress and apoptosis. Biomed. Pharmacother. 126, 110056.

Hudson, B. D., Shimpkude, B., Mackenzie, A. E., Butcher, A. J., Pediani, J. D., Christiansen, E., Heathcote, H., Tobin, A. B., Ulven, T. and Milligan, G. (2013) The pharmacology of TUG-591, a potent and selective agonist of the free fatty acid receptor 4 (FFA4-GPR120), demonstrates both potential opportunity and possible challenges to therapeutic agonism. Mol. Pharmacol. 84, 710-725.

Ichimura, A., Hirasaki, A., Poulan-Godefroy, O., Bonnefon, A., Hara, T., Yengo, L., Kimura, K., Leloir, A., Liu, N. and Iida, K. (2012) Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human. Nature 483, 350-354.

Im, D. S. (2012) Omega-3 fatty acids in anti-inflammation (pro-resolution) and GPCRs. Prog. Lipid Res. 51, 232-237.

Im, D. S. (2013) Intercellular lipid mediators and GPCR drug discov-
GPR120 agonist TUG-891 promotes metabolic health by stimulating mitochondrial respiration in brown fat. *EMBO Mol. Med.* **10**, e8047.

Serhan, C. N., Chiang, N. and Dalli, J. (2018) New pro-resolving n-3 mediators bridge resolution of infectious inflammation to tissue regeneration. *Mol. Aspects Med.* **64**, 1-17.

Shimpuka, B., Hudson, B. D., Hovgaard, C. K., Milligan, G. and Ulven, T. (2012) Discovery of a potent and selective GPR120 agonist. *J. Med. Chem.* **55**, 4511-4515.

Son, S. E., Park, S. J., Koh, J. M. and Im, D. S. (2020) Free fatty acid receptor 4 (FFA4) activation ameliorates 2,4-dinitrochlorobenzene-induced atopic dermatitis by increasing regulatory T cells in mice. *Acta Pharmacol. Sin.* **41**, 1337-1347.

Song, T., Zhou, Y., Peng, J., Tao, Y. X., Yang, Y., Xu, T., Peng, J., Ren, J., Xiang, Q. and Wei, H. (2016) GPR120 promotes adipogenesis through intracellular calcium and extracellular signal-regulated kinase 1/2 signal pathway. *Mol. Cell. Endocrinol.* **343**, 1-13.

Sparks, S. K., Chen, G., Collins, J. L., Danger, D., Dock, S. T., Jayawickram, C. E., Jenkinson, S., Laudeman, C., Leesnitzer, M. A., Liang, Y., Moraes-Vieira, P. M., Zhang, T., Herman, M. J., Syed, I., M. K. J., and Ross, S. (2014) Identification of diarylpropionic acids as agonists of the free fatty acid receptor 4 (FFA4)/GPR120. *Bioorg. Med. Chem. Lett.* **24**, 3100-3103.

Stone, V. M., Dhayal, S., Brocklehurst, K. J., Lenaghan, C., Sorhede, M., Winzell, M., Hammad, M., Xu, X., Smith, D. M. and Morgan, N. G. (2014) GPR120 (FFAR4) is preferentially expressed in pancreatic ducts and regulates somatostatin secretion from murine islets of Langerhans. *Diabetologia* **57**, 1182-1191.

Su, X. L., Liu, Y. G., Shi, M., Zhao, Y. Y., Liang, X. Y., Zhang, L. J., Wei, L. L. and Zhao, Y. F. (2020) The GPR120 agonist TUG-891 inhibits the motility and phagocytosis of mouse alveolar macrophages. *Biomed. Res. Int.* **2020**, 1706168.

Suckow, A. T. and Briscoe, C. P. (2017) Key questions for translation of FFA receptors: from pharmacology to medicines. *Handb. Exp. Pharmacol.* **236**, 101-131.

Sun, M., Wu, W., Liu, Z. and Cong, Y. (2017) Microbiota metabolite short chain fatty acids, GPCR, and inflammatory bowel diseases. *J. Gastroenterol.* **52**, 1-8.

Sun, Q., Hirasawa, A., Hara, T., Kimura, I., Adachi, T., Awaji, T., Fujieda, H., Ishiguro, M., Suzuiki, T., Miyata, N. and Tsujimoto, G. (2010) Structure-activity relationships of GPR120 agonists based on a docking simulation. *Mol. Pharmacol.* **78**, 804-810.

Suzuki, T., Igar, S., Hirasawa, A., Hata, M., Ishiguro, M., Fujieda, H., Itoh, Y., Hirano, T., Nakagawa, H., Ogura, M., Makishima, M., Tsujimoto, G. and Miyata, N. (2008) Identification of G protein-coupled receptor 120-selective agonists derived from PPAR agonists. *J. Med. Chem.* **51**, 7640-7644.

Takahashi, K., Fukushima, K., Onishi, Y., Minami, K., Otagaki, S., Ishimoto, K., Fukushima, N., Honoki, K. and Tsujuchi, T. (2018) Involvement of FFA1 and FFA4 in the regulation of cellular functions during tumor progression in colon cancer cells. *Exp. Cell Res.* **369**, 54-60.

Takahashi, K., Fukushima, K., Onishi, Y., Noda, Y., Inui, K., Fukushima, N., Honoki, K. and Tsujuchi, T. (2017) Different effects of G-protein-coupled receptor 120 (GPR120) and GPR40 on cell motile activity of highly migratory osteosarcoma cells. *Biochem. Biophys. Res. Commun.* **484**, 675-680.

Tan, J. K., McKenzie, C., Marinho, E., Macia, L. and Mackay, C. R. (2017) Metabolite-sensing G protein–coupled receptors—facilitators of diet-related immune regulation. *Annu. Rev. Immunol.* **35**, 371-402.

Ulven, T. and Christiansen, E. (2015) Dietary fatty acids and their potential for controlling metabolic diseases through activation of FFA4/GPR120. *Annu. Rev. Nutr.* **35**, 239-263.

Villegas-Comonfort, S., Takei, Y., Tsujimoto, G., Hirasawa, A. and Garcia-Sainz, J. A. (2017) Effects of arachidonic acid on FFA4 receptor: Signaling, phosphorylation and internalization. *Prostaglandins Leukot. Essent. Fatty Acids* **117**, 1-10.

Wang, C., Liu, Y., Pan, Y. and Jin, H. (2020) Effect of GSK-137647A, the first non-carboxylic FFA4 agonist, on the osteogenic and adipogenic differentiation of bone mesenchymal stem cells in db/db mice. *J. Pharm. Pharmacol.* **72**, 461-469.

Wang, Y., Xie, T., Zhang, D. and Leung, P. S. (2019) GPR120 protects lipotoxicity-induced pancreatic β-cell dysfunction through regulation of PDX1 expression and inhibition of islet inflammation. *Clin. Sci. (Lond)* **133**, 101-116.

Watterson, K. R., Hansen, S. V., Hudson, B. D., Alvarez-Curto, E., Rajhan, S. Z., Azvedo, C. M., Martin, G., Dunlop, J., Aywood, S. J. and Ulven, T. (2017) Probe-dependent negative allosteric modulators of the long-chain free fatty acid receptor FFA4. *Mol. Pharmacol.* **91**, 630-641.

Wellhauser, L. and Belsham, D. D. (2014) Activation of the omega-3 fatty acid receptor GPR120 mediates anti-inflammatory actions in immortalized hypothalamic neurons. *J. Neuroinflammation* **11**, 60.

Wu, Q., Wang, H., Zhao, X., Shi, Y., Jin, M., Wan, B., Xu, H., Cheng, Y., Ge, H. and Zhang, Y. (2013) Identification of G-protein-coupled receptor 120 as a tumor-promoting receptor that induces angiogenesis and migration in human colorectal carcinoma. *Oncoogene* **32**, 5541-5550.

Yore, M. M., Syed, I., Moraes-Vieira, P. M., Zhang, T., Herman, M. A., Homan, E. A., Patel, R. T., Lee, J., Chen, S. and Peroni, O. D. (2014) Discovery of a class of endogenous mammalian lipids with anti-diabetic and anti-inflammatory effects. *Cell* **159**, 318-332.

Zhao, C., Zhou, J., Meng, Y., Shi, N., Wang, X., Zhou, M., Li, G. and Yang, Y. (2020) DHA sensor GPR120 in host defense exhibits the dual characteristics of regulating dendritic cell function and skewing the balance of Th17/Tregs. *Int. J. Biol. Sci.* **16**, 374-387.

Zhao, J., Wang, H., Shi, P., Wang, W. and Sun, Y. (2017) GPR120, a potential therapeutic target for experimental colitis in IL-10 deficient mice. *Oncotarget* **8**, 8397-8405.

Zhai, J., Wei, H., Wang, X., Zhang, B., Wei, L. L., Zhu, J. X., Chen, M. W. and Zhao, Y. F. (2019) Lipopolysaccharide inhibits GPR120 expression in macrophages via Toll-like receptor 4 and p38 MAPK activation. *Cell Biol. Int. doi: 10.1002/cbin.11204 [Online ahead of print].

https://doi.org/10.4062/biomolther.2020.213